Improving access to liver transplantation: Another part of the puzzle
Janet E. Tuttle‐Newhall, Krista L. Lentine – 27 March 2013
Serum alpha‐fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma
Kristin Berry, George N. Ioannou – 27 March 2013 – We aimed to determine whether combining serum alpha‐fetoprotein (AFP) level with hepatocellular carcinoma (HCC) tumor burden would allow better stratification of posttransplant survival for patients with HCC undergoing liver transplantation. Adjusting for donor and recipient characteristics, we calculated the risk of posttransplant mortality associated with serum AFP level or HCC tumor burden for all first‐time adult liver transplants performed in the United States between 2002 and 2011 (n = 45,267).
Prevention of de novo hepatitis B with adefovir plus vaccination in recipients of liver transplants from core antibody–positive donors
Matthew S. Chang, Sonja K. Olsen, Elsa M. Pichardo, Scott Heese, Jessica B. Stiles, James V. Guarrera, Jean C. Emond, Robert S. Brown – 27 March 2013
Reply:
Ching‐Lung Lai, Man‐Fung Yuen – 26 March 2013
Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients
Carlos Benítez, María‐Carlota Londoño, Rosa Miquel, Tommaso‐Maria Manzia, Juan G. Abraldes, Juan‐José Lozano, Marc Martínez‐Llordella, Marta López, Roberta Angelico, Felix Bohne, Pilar Sese, Frederic Daoud, Patrick Larcier, Dave L. Roelen, Frans Claas, Gavin Whitehouse, Jan Lerut, Jacques Pirenne, Antoni Rimola, Giuseppe Tisone, Alberto Sánchez‐Fueyo – 26 March 2013 – Lifelong immunosuppression increases morbidity and mortality in liver transplantation.
Adenosine kinase is a key determinant for the anti‐HCV activity of ribavirin
Kyoko Mori, Osamu Hiraoka, Masanori Ikeda, Yasuo Ariumi, Akiko Hiramoto, Yusuke Wataya, Nobuyuki Kato – 26 March 2013 – Ribavirin (RBV) is often used in conjunction with interferon‐based therapy for patients with chronic hepatitis C.
Smart applications for assessing minimal hepatic encephalopathy: Novelty from the app revolution
Piero Amodio, Juan Cordoba – 26 March 2013
Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer
Jiayi Wang, Lifang Ma, Wenhao Weng, Yongxia Qiao, Yue Zhang, Jiangtu He, Hongmei Wang, Weifan Xiao, Lanlan Li, Qinghua Chu, Qiuhui Pan, Yongchun Yu, Fenyong Sun – 26 March 2013 – Yes‐associated protein (YAP), the downstream effecter of the Hippo‐signaling pathway as well as cyclic adenosine monophosphate response element‐binding protein (CREB), has been linked to hepatocarcinogenesis. However, little is known about whether and how YAP and CREB interact with each other.
Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection
Shirin Ashraf, Katja Nitschke, Usama M. Warshow, Collin R. Brooks, Arthur Y. Kim, Georg M. Lauer, Theresa J. Hydes, Matthew E. Cramp, Graeme Alexander, Ann‐Margaret Little, Robert Thimme, Christoph Neumann‐Haefelin, Salim I. Khakoo – 26 March 2013 – CD8+ T‐cell responses to hepatitis C virus (HCV) are important in generating a successful immune response and spontaneously clearing infection. Human leukocyte antigen (HLA) class I presents viral peptides to CD8+ T cells to permit detection of infected cells, and tapasin is an important component of the peptide loading complex for HLA class I.
Genotype‐phenotype relationships in the low‐phospholipid‐associated cholelithiasis syndrome: A study of 156 consecutive patients
Raoul Poupon, Olivier Rosmorduc, Pierre Yves Boëlle, Yves Chrétien, Christophe Corpechot, Olivier Chazouillères, Chantal Housset, Véronique Barbu – 26 March 2013 – The low‐phospholipid‐associated cholelithiasis syndrome (LPAC; OMIM 171060) is a peculiar form of intrahepatic cholelithiasis occurring in young adults, associated with ABCB4/MDR3 gene sequence variations. Our aim was to determine the genotype‐phenotype relationships in 156 consecutive patients with the criteria of LPAC syndrome.